一个非常规的守门员突变使伊诺西六基酸盐激酶对全抑制剂敏感
Tim Aguirre1,2, Gillian L Dornan1, Sarah Hostachy1
1Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany.
eLife
|October 16, 2023
概括
研究人员开发了一种新的模拟敏感方法,以发现因诺西六酸酶 (IP6Ks) 的抑制剂. 化合物FMP-201300选择性地向IP6K1和IP6K2突变,为研究这些与疾病相关的酶提供了一个新的工具.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 酶学 是一种酶学.
背景情况:
- 伊诺西六酸激酶 (IP6Ks) 涉及到各种疾病表型.
- 开发哺乳动物IP6K异酶的选择性抑制剂对于药理学研究至关重要.
- 缺乏特定工具阻碍了研究单个IP6K功能的研究.
研究的目的:
- 实施对IP6K抑制剂发现的模拟敏感方法.
- 为了确定哺乳动物IP6K同酶的强效和选择性抑制剂.
- 描述已识别的抑制剂的作用机制.
主要方法:
- 一个模拟敏感的IP6K库的高通量选.
- 化合物的生物化学验证.
- 二交换质谱法 (HDX-MS) 用于阐明结合机制.
主要成果:
- 确定FMP-201300作为IP6K1和IP6K2守门者突变的强大和选择性抑制剂.
- 已经证明了FMP-201300.00的全性作用机制.
- HDX-MS揭示了FMP-201300与ATP结合部位相邻的全囊结合,由门卫突变诱导的螺旋体位移促进.
结论:
- FMP-201300是开发选择性IP6K抑制剂的有价值的化合物.
- 对模拟敏感的方法提供了一个针对特定IP6K异酶的平台.
- 这项工作可以进一步开发IP6K研究和治疗应用的药理工具.
更多相关视频
08:07Identification of Inositol Phosphate or Phosphoinositide Interacting Proteins by Affinity Chromatography Coupled to Western Blot or Mass Spectrometry
Published on: July 26, 2019
8.6K
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.9K
相关概念视频
Allosteric Regulation
58.1K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
